$27.01 -$0.43 (-1.6%)

04:30 PM EDT on 04/24/19

Editas Medicine (NASDAQ:EDIT)

CAPS Rating: 5 out of 5

Current Price $27.01 Mkt Cap $1.3B
Open $27.52 P/E Ratio 0.00
Prev. Close $27.44 Div. (Yield) $0.00 (0.0%)
Daily Range $26.49 - $27.60 Volume 207,187
52-Wk Range $19.01 - $28.15 Avg. Daily Vol. 21

Caps

How do you think NASDAQ:EDIT will perform against the market?

Add Stock to CAPS Watchlist

All Players

235 Outperform
8 Underperform
 

All-Star Players

99 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:EDIT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rhallbick (95.29)
Submitted April 15, 2018

Editas Medicine (NASDAQ: EDIT) is a biotech specializing in CRISPR-Cas9 research and development. CRISPR has promise for the treatment of patients with genetically defined diseases by correcting their disease?causing genes.CRISPR is an acronym for… More

btechrisk11 (< 20)
Submitted April 15, 2018

Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.

NASDAQ:EDIT VS S&P 500 (SPY)

NASDAQ:EDIT Summary

Fools bullish on NASDAQ:EDIT are also bullish on:

Fools bearish on NASDAQ:EDIT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EDIT.

Recs

0
Member Avatar LastPlaceLenny (50.18) Submitted: 3/15/2019 3:26:17 AM : Underperform Start Price: $24.03 NASDAQ:EDIT Score: -8.22

Not ready to take off yet, will out perform in long run, but not sure when that long run starts. Not this year.

Recs

0
Member Avatar LazyHarlequin (82.62) Submitted: 12/21/2018 4:12:55 PM : Underperform Start Price: $18.00 NASDAQ:EDIT Score: -27.78

On 12/21/18 down $4.68 to $18.28. Options available.

Recs

0
Member Avatar future21 (73.14) Submitted: 11/12/2018 4:18:59 PM : Outperform Start Price: $28.49 NASDAQ:EDIT Score: -12.22

Promising technology but this is admittedly a bit of a bet... there are no guarantees in biotech. I already picked Intellia, and due to these two companies having the only legitimate claims on patents in this field that I know of (other than Crispr), it only makes sense to take a basket approach with these. Editas is entering preliminary FDA trials. Editas also won the Broad case. It looks to me like Editas is now in the best position to profit from this technology if it proves effective and safe.

As a side note, I have closed my position in CRISPR for now, as it has made gains above and beyond the other two companies without any concrete evidence that it should have, in my opinion. **This is NOT consistent with my general investing strategy, however neither is gambling (more or less) on biotech. My theory behind the rise in CRISPR relative to EDIT and NTLA is that it is identical in name to the technology, and thus likely the first company anyone sees when researching this. For that reason, mixed with the results of the Broad case and the fact that NTLA is working off the same patent family as CRISPR and I've already staked a position in that, it made sense to move forward with EDIT and NTLA as my basket. This 5+ year call comes with the caveat that I'm both a new investor and consider this very risky even as a young investor, and will not be nearly equal in weight to my other positions.

This is essentially a small-stake aimed at diversifying a tech, advertising, and consumer goods heavy portfolio.

Leaderboard

Find the members with the highest scoring picks in EDIT.

Score Leader

PAGEBOY73

PAGEBOY73 (98.83) Score: +120.59

The Score Leader is the player with the highest score across all their picks in EDIT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
SeriousK 28.96 3/9/2016 Underperform 5Y $42.70 -36.74% +46.61% +83.35 0 Comment
TimeToBuy 86.75 3/10/2016 Underperform 5Y $32.50 -16.89% +46.17% +63.06 0 Comment
freemarketmike < 20 6/7/2017 Outperform 5Y $15.43 +75.01% +20.01% +55.00 1 Comment
WoollyWombat < 20 9/16/2016 Outperform 5Y $14.48 +86.53% +36.99% +49.54 0 Comment
CMFMLove 42.83 6/13/2017 Outperform 5Y $16.00 +68.81% +19.80% +49.02 1 Comment
FunesDMemorious 97.07 10/26/2016 Outperform 5Y $14.55 +85.64% +37.09% +48.55 0 Comment
Playa14 < 20 6/9/2017 Outperform 5Y $16.08 +67.97% +19.74% +48.23 0 Comment
portefeuille 98.18 2/10/2016 Outperform 5Y $13.26 +103.70% +56.74% +46.95 0 Comment
portefeuille2 99.06 9/22/2016 Outperform 5Y $14.87 +81.64% +34.71% +46.93 0 Comment
nobody2013 < 20 3/10/2016 Underperform NS $26.79 +0.82% +47.42% +46.59 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EDIT.

Advertisement